©2024 Stanford Medicine
Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study
Recruiting
I'm InterestedTrial ID: NCT03680781
Purpose
This study evaluates the effectiveness of re-treatment using accelerated schedule of
intermittent theta-burst stimulation for treatment-resistant depression. This is an open
label study.
Official Title
Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study
Stanford Investigator(s)
Ian H. Kratter, MD, PhD
Clinical Assistant Professor, Psychiatry and Behavioral Sciences
Nolan Williams
Associate Professor of Psychiatry and Behavioral Sciences (Major Laboratories & Clinical Translational Neurosciences Incubator) and, by courtesy, of Radiology (Neuroimaging and Neurointervention)
Eligibility
Inclusion Criteria:
- Male or female, 18 to 75 years of age.
- Able to provide informed consent.
- Diagnosed with Major Depressive Disorder (MDD) or bipolar affective disorder 2 and
currently experiencing a Major Depressive Episode (MDE).
- prior exposure to rTMS
- Participants must qualify as "moderate or severe treatment refractory" using the
Maudsley staging method.
- Participants may continue antidepressant regimen, but must be stable for 6 weeks prior
to enrollment in the study. They must maintain that same antidepressant regimen
throughout the study duration.
- Participants are required to have a stable psychiatrist for the duration of study
enrollment.
Exclusion Criteria:
- History of MI, CABG, CHF, or other cardiac history
- Any neurological conditions
- History of epilepsy
- OCD
- Independent sleep disorder
- Autism Spectrum Disorder
Intervention(s):
device: Intermittent theta-burst stimulation (iTBS)
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Claudia Tischler, BA
650-498-8535